|
|
|
|
Sanofi-aventis Video Q&A : CEO Chris Viehbacher Comments on 2009 Full-Year Earnings
Sanofi-aventis, one of the worlds largest diversified healthcare companies, reports earnings for the full-year 2009.CEO Chris Viehbacher comments on earnings and outlook. Use these links to watch the video interview in the format of your choice. Windows...
|
|
|
Sanofi-aventis Video Q&A : CEO Chris Viehbacher Comments on 2009 Full-Year Earnings
PARIS--(BUSINESS WIRE)--Sanofi-aventis, one of the worlds largest diversified healthcare companies, reports earnings for the full-year 2009.CEO Chris Viehbacher comments on earnings and outlook.Use these links to watch the video interview in the format of...
|
|
|
Sanofi-aventis Video Q&A : CEO Chris Viehbacher Comments on 2009 Full-Year Earnings
Sanofi-aventis, one of the world's largest diversified healthcare companies, reports earnings for the full-year 2009.CEO Chris Viehbacher comments on earnings and outlook. Use these links to watch the video interview in the format of your choice: Windows...
|
|
|
Sanofi-aventis Video Q&A : CEO Chris Viehbacher Comments on 2009 Full-Year Earnings
Sanofi-aventis, one of the world's largest diversified healthcare companies, reports earnings for the full-year 2009.CEO Chris Viehbacher comments on earnings and outlook. Use these links to watch the video interview in the format of your choice: Windows...
|
|
|
Sanofi-aventis Video Q&A: CEO Chris Viehbacher Comments on 2009 Full-Year Earnings
Sanofi-aventis, one of the world's largest diversified healthcare companies, reports earnings for the full-year 2009.CEO Chris Viehbacher comments on earnings and outlook. Use these links to watch the video interview in the format of your choice: Windows...
|
|
|
Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
The global Acute Coronary Syndrome (ACS) market was valued at $1,021m in 2009 and is forecast to decline by 1% annually for the next seven years to reach $949m in 2016.This decline in market size is primarily due to the patent expirations of six branded...
|
|
|
Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
The Acute Coronary Syndrome Market is Estimated to Shrink at a Compound Annual Growth Rate (CAGR) of 1% from 2009 to 2016 FOR IMMEDIATE RELEASE PR Log (Press Release) Feb 08, 2010 The global Acute Coronary Syndrome (ACS) market was valued at $1,021m in 2009 and...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Clears Drug Chief of Conflict
WASHINGTONThe inspector general of the Department of Health and Human Services has cleared the chief of the drug division at the Food and Drug Administration of allegations of conflict of interest stemming from her interactions with scientists at a...
|
|
|
PREVIEW-Sanofi Q4 seen up, cautious for 2010
t 0730 GMT * Q4 adj.net seen up 3.5 pct at 1.684 bln euros * Q4 sales seen up 4 pct at 7.371 bln ($10.23 billion) * 2010 EPS forecasts from dip to low single-digit growth * Updates on generics, Lovenox, Merial-ISP JV PARIS, Feb 5 (Reuters) - French...
|
|
|
Urologists prevent DVTs with checklists, AUA policy
Deep vein thrombosis is among the most common surgical complications experienced by urologists.In 2009, AUA released a best practice policy statement that provides an expert panel's recommendations for the prevention of DVTs. Urology Times talked to...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a conflict...
|
|
|
Sanofi-Aventis Creates Joint Venture In China
INDIANAPOLIS (AP) -- French drugmaker Sanofi-Aventis said Friday it has formed a joint venture with Chinese drugmaker Minsheng Pharmaceutical Co.focusing mostly on vitamins and mineral supplements. The joint venture focuses on the largest consumer...
|
|
|
Exane BNP Paribas assigns 'outperform' to Sanofi-Aventis
- Exane BNP Paribas upgraded the rating of French pharmaceuticals group Sanofi-Aventis (EPA:SAN) to 'outperform' from 'neutral', raising the price target on the stock to EUR 65 from EUR 56.The broker estimated that the risk of the imminent launch of a...
|
|
|
Exane cuts Bayer, upgrades Sanofi, Shire
LONDON (MarketWatch) -- Exane BNP-Paribas on Monday shuffled some of its ratings in the European pharmaceutical sector.The broker lowered German firm Bayer to neutral from outperform, noting that the stock outperformed its composite index by 14% in 2009 due...
|
